Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.45 |
| ▸ | RELA | Q04206 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18570971 | 1.00 | GAA (0.54) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL570801 | 0.83 | GAA (0.54) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL8222638 | 0.83 | GAA (0.49) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL20377683 | 0.81 | GAA (0.56) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL9846492 | 0.80 | GAA (0.53) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL2936974 | 0.80 | GAA (0.53) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL3307631 | 0.80 | GAA (0.53) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL31246142 | 0.80 | BTK (0.53) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL24248759 | 0.78 | GAA (0.51) | GAABTKNFKB1NFKB2RELA | |
| SCHEMBL29363535 | 0.78 | GAA (0.53) | GAABTKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783199-A | Pyrazolo [1,5-A ] pyrazine derivatives as BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2007136603-A2 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007126745-A2 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | GAA 3100/4885BTK 1/4885NFKB1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.